- Mechanism
- Stimulates melanogenesis via MC1R activation
- Typical research dose
- 250-500 mcg/day (MT-2) subcutaneous
- Route
- topical, subcutaneous
- Half-life
- ~30-60 mins (MT-1), 1-2 hours (MT-2)
- Legal status
- FDA Approved (MT-1 derivative), Research Only (MT-2)
Overview
Melanotan I & II (MT-1/MT-2) are synthetic analogs of the naturally occurring alpha-melanocyte-stimulating hormone (alpha-MSH). The Melanotan I & II (MT-1/MT-2) peptide primarily functions by binding to melanocortin receptors, stimulating melanin production to induce skin pigmentation without requiring UV exposure. Researchers actively investigate these peptides for their diverse physiological effects, which include enhanced tanning, potential appetite suppression, and significant impacts on sexual health and arousal. Understanding these compounds is crucial for developing novel treatments for phototoxicity and metabolic disorders.
Potential Benefits
- Skin Pigmentation and Tanning: Stimulates melanogenesis by activating MC1 receptors, leading to increased melanin production and skin darkening without UV exposure.
- Photoprotection: May offer protective effects against UV-induced skin damage by increasing baseline melanin levels prior to sun exposure.
- Enhanced Libido and Sexual Function: MT-2 specifically activates MC3 and MC4 receptors in the central nervous system, significantly increasing arousal and erectile function.
- Appetite Suppression: Activation of the melanocortin system via MC4 receptors demonstrates a reduction in food intake and potential weight-loss benefits.
- Anti-inflammatory Effects: Alpha-MSH analogs exhibit systemic anti-inflammatory properties by modulating immune cell responses and reducing pro-inflammatory cytokines.
Where to Buy Melanotan I & II (MT-1/MT-2)
Research compound. Melanotan I & II (MT-1/MT-2) is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Nausea and gastrointestinal discomfort shortly after administration.
- Facial flushing and transiently increased body temperature.
- Spontaneous erections or increased sexual arousal (primarily MT-2).
- Lethargy or mild fatigue.
- Darkening of existing moles, freckles, and hyperpigmentation.
Rare or serious side effects:
- Melanoma or atypical melanocytic lesions (long-term risk under investigation).
- Cardiovascular effects including elevated blood pressure.
- Priapism (prolonged, painful erections requiring medical intervention).
- Renal infarction or kidney damage associated with unregulated use.
Melanotan I & II (MT-1/MT-2) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Receptor activation drives the primary mechanism of the Melanotan I & II (MT-1/MT-2) peptide, as both compounds act as non-selective agonists of the melanocortin receptors (MC1R through MC5R). By binding to MC1R on melanocytes, these peptides trigger a signaling cascade involving cyclic AMP (cAMP) that upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis. This biochemical pathway effectively mimics the body's natural response to sunlight, promoting melanogenesis and subsequent skin darkening without requiring ultraviolet radiation. Central nervous system modulation distinguishes MT-2 from MT-1, as MT-2 readily crosses the blood-brain barrier to interact with MC3R and MC4R. The activation of these specific central receptors regulates energy homeostasis, leading to appetite suppression, while simultaneously stimulating autonomic pathways that control sexual arousal and erectile function. Consequently, researchers studying Melanotan I & II (MT-1/MT-2) benefits often note the broader systemic impact of MT-2 compared to the more localized dermatological effects of MT-1.
Origin & History
Initial development of Melanotan peptides began in the 1980s at the University of Arizona (Dorr et al., 1996), where researchers sought a sunless tanning agent to reduce the incidence of skin cancer. Scientists synthesized these alpha-MSH analogs to be more stable and potent than the naturally occurring hormone, leading to the creation of both the linear MT-1 (afamelanotide) and the cyclic MT-2. Early clinical trials demonstrated significant efficacy in inducing pigmentation, prompting further investigation into their secondary effects on weight loss and sexual health. Regulatory status varies significantly between the two variants, with MT-1 achieving clinical approval in several regions under the brand name Scenesse for treating erythropoietic protoporphyria (EPP). Conversely, MT-2 remains strictly a research-only chemical due to its broader receptor affinity and higher incidence of adverse events. Despite widespread unregulated use, health authorities consistently warn about Melanotan I & II (MT-1/MT-2) side effects, emphasizing that unapproved formulations pose substantial health risks.